Key Takeaways Effectiveness: Tirzepatide may lead to greater average weight loss in trial populations
The answer is that unlike the people in his study who needed to find a maintenance dosea situation that does not currently have a standard of carepeople who have never taken a GLP-1 drug have a standard protocol backed by robust evidence to follow
Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1renal axis in man
By shrinking visceral fat stores, GLP-1s help decrease the release of inflammatory cytokines, which contributes to improved blood sugar control, lower blood pressure, and a healthier lipid profile
1- Robust Weight Reduction : Demonstrates significant, dose-dependent[6] weight loss, with non-diabetic adults achieving 12.1 kg to 17.9 kg reductions over 72 weeks
If ongoing trials continue to demonstrate safety and effectiveness, regulatory approval could occur after the completion of these studies
